Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation

Journal of Hepatology

Volumn 70, Issue 4, 2019, Pages 666-673

  Goldaracena, Nicolas ^a   Gorgen, Andre ^a   Doyle, Adam ^a   Hansen, Bettina E ^b   Tomiyama, Koji ^a   Zhang, Wei ^a   Ghanekar, Anand ^a   Lilly, Les ^a   Cattral, Mark ^a   Galvin, Zita ^a   Selzner, Markus ^a   Bhat, Mamatha ^a   Selzner, Nazia ^a   McGilvray, Ian ^a   Greig, Paul D ^a   Grant, David R ^a   Sapisochin, Gonzalo ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Deceased donor; Hepatoma; Intention to treat; Liver cancer; Living donor

Indexed keywords

ADULT; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DECEASED DONOR; DISEASE SEVERITY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; INTENTION TO TREAT ANALYSIS; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RISK; PRIORITY JOURNAL; SURVIVAL RATE; AGED; CADAVER; GRAFT SURVIVAL; HOSPITAL ADMISSION; KAPLAN MEIER METHOD; LIVER TUMOR; MORTALITY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR;

AGED; CADAVER; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; WAITING LISTS;

EID: 85061146041     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2018.12.029     Document Type: Article

References (29)

1. Shah, S.A., Levy, G.A., Greig, P.D., Smith, R., McGilvray, I.D., Lilly, L.B., et al. Reduced mortality with right-lobe living donor compared to deceased-donor liver transplantation when analyzed from the time of listing. Am J Transplant 7 (2007), 998–1002.
2. Berg, C.L., Gillespie, B.W., Merion, R.M., Brown, R.S., Abecassis, M.M., Trotter, J.F., et al. Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology 133 (2007), 1806–1813.
3. Fisher, R.A., Kulik, L.M., Freise, C.E., Lok, A.S., Shearon, T.H., Brown, R.S., et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 7 (2007), 1601–1608.
4. Kulik, L.M., Fisher, R.A., Rodrigo, D.R., Brown, R.S., Freise, C.E., Shaked, A., et al. Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort. Am J Transplant 12 (2012), 2997–3007.
5. Grant, R.C., Sandhu, L., Dixon, P.R., Greig, P.D., Grant, D.R., McGilvray, I.D., Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis. Clin Transplant 27 (2013), 140–147.
6. Lo, C.M., Fan, S.T., Liu, C.L., Chan, S.C., Ng, I.O., Wong, J., Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg 94 (2007), 78–86.
7. Azoulay, D., Audureau, E., Bhangui, P., Belghiti, J., Boillot, O., Andreani, P., et al. Living or brain-dead donor liver transplantation for hepatocellular carcinoma: a multicenter, western, intent-to-treat cohort study. Ann Surg 266 (2017), 1035–1044.
8. Bhangui, P., Vibert, E., Majno, P., Salloum, C., Andreani, P., Zocrato, J., et al. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation. Hepatology 53 (2011), 1570–1579.
9. Sapisochin, G., Goldaracena, N., Laurence, J.M., Levy, G.A., Grant, D.R., Cattral, M.S., Right lobe living-donor hepatectomy-the Toronto approach, tips and tricks. Hepatobiliary Surg Nutr 5 (2016), 118–126.
10. Gorgen, A., Goldaracena, N., Zhang, W., Rosales, R., Ghanekar, A., Lilly, L., et al. Surgical complications after right hepatectomy for live liver donation: largest single-center western world experience. Semin Liver Dis, 2018.
11. Heimbach, J., Kulik, L.M., Finn, R., Sirlin, C.B., Abecassis, M., Roberts, L.R., et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology, 2017.
12. Sapisochin, G., Goldaracena, N., Laurence, J.M., Dib, M., Barbas, A., Ghanekar, A., et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study. Hepatology 64 (2016), 2077–2088.
13. TGLN. Ontario's Adult Referral and Listing Criteria for Liver Transplantation. Trillium Gift of Life Network. https://www.giftoflife.on.ca/resources/pdf/5_Adult_Liver_TxRef_List_Criteria_Dec417.pdf Published 2017. [Accessed 5 December 2018].
14. Toso, C., Trotter, J., Wei, A., Bigam, D.L., Shah, S., Lancaster, J., et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 14 (2008), 1107–1115.
15. Yao, F.Y., Xiao, L., Bass, N.M., Kerlan, R., Ascher, N.L., Roberts, J.P., Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 7 (2007), 2587–2596.
16. Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996), 693–699.
17. Sapisochin, G., Barry, A., Doherty, M., Fischer, S., Goldaracena, N., Rosales, R., et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol 67 (2017), 92–99.
18. Vibert, E., Azoulay, D., Hoti, E., Iacopinelli, S., Samuel, D., Salloum, C., et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 10 (2010), 129–137.
19. Ruopp, M.D., Perkins, N.J., Whitcomb, B.W., Schisterman, E.F., Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection. Biom J 50 (2008), 419–430.
20. Fine, J., Gray, R., A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999), 496–509.
21. Mehta, N., Heimbach, J., Lee, D., Dodge, J.L., Harnois, D., Burns, J., et al. Wait time of less than 6 and greater than 18 months predicts hepatocellular carcinoma recurrence after liver transplantation: proposing a wait time “sweet spot”. Transplantation 101 (2017), 2071–2078.
22. Heimbach, J.K., Hirose, R., Stock, P.G., Schladt, D.P., Xiong, H., Liu, J., et al. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States. Hepatology 61 (2015), 1643–1650.
23. Samoylova, M.L., Dodge, J.L., Yao, F.Y., Roberts, J.P., Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 20 (2014), 937–944.
24. Halazun, K.J., Patzer, R.E., Rana, A.A., Verna, E.C., Griesemer, A.D., Parsons, R.F., et al. Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology 60 (2014), 1957–1962.
25. OPTN. Organ Procurement and Transplantation Network – Policies. https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf#nameddest=Policy_09 Published 2018. [Accessed 5 December 2018].
26. Wan, P., Zhang, J.J., Li, Q.G., Xu, N., Zhang, M., Chen, X.S., et al. Living-donor or deceased-donor liver transplantation for hepatic carcinoma: a case-matched comparison. World J Gastroenterol 20 (2014), 4393–4400.
27. Xiao, G.Q., Song, J.L., Shen, S., Yang, J.Y., Yan, L.N., Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation. World J Gastroenterol 20 (2014), 10953–10959.
28. Lai, Q., Nicolini, D., Inostroza Nunez, M., Iesari, S., Goffette, P., Agostini, A., et al. A novel prognostic index in patients with hepatocellular cancer waiting for liver transplantation: time-radiological-response-alpha-fetoprotein-INflammation (TRAIN) score. Ann Surg 264 (2016), 787–796.
29. Halazun, K.J., Tabrizian, P., Najjar, M., Florman, S., Schwartz, M., Michelassi, F., et al. Is it time to abandon the milan criteria?: Results of a bicoastal US collaboration to redefine hepatocellular carcinoma liver transplantation selection policies. Ann Surg, 2018.